NuLife Sciences Inc. (OTCQB: NULF), is a biomedical company focused on advancing human organ transplant technology and medical research which could potentially eliminate the need for organ or tissue match and anti-rejection drugs.

1. THE FUTURE OF TRANSPLANTS
February 2017

2. 2
Safe Harbor
The following discussion, in addition to the other information contained in this presentation, should be considered carefully in
evaluating our prospects. This presentation (including without limitation the following factors that may affect operating results)
contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Words
such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking
statements in this presentation. Additionally, statements concerning future matters such as revenue projections, projected
profitability, growth strategies, and other statements regarding matters that are not historical are forward-looking statements.
Forward-looking statements in this presentation reflect the good faith judgment of our management and the statements are based
on facts and factors as we currently know them. Forward-looking statements are subject to risks and uncertainties and actual
results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Factors
that could cause or contribute to such differences in results and outcomes include, but are not limited to, those discussed in this
presentation. Readers are urged not to place undue reliance on these forward-looking statements which speak only as of the date
of this presentation. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or
circumstance that may arise after the date of this presentation.
This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any
securities of the Company nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

3. 3
Company Overview
NuLife Sciences Inc. (OTCQB: NULF), is a biomedical company focused on
advancing human organ transplant technology and medical research which
could potentially eliminate the need for organ or tissue match and
anti-rejection drugs.
NuLife’s mission is to change the face of organ transplantation as we know it today:
• Recipients will no longer have to wait, often for years, for a matched organ
• Reduces or eliminates the need for dialysis for patients waiting for a match
• Eliminates the need for anti-rejection drugs, significantly improving the quality of life
• Substantial potential costs savings to the system from reduced Rx and dialysis

4. 4
Investment Highlights
• Novel, patented technique with the potential to transform the
transplantation market
• Massive need and market for organ transplants with over 123K
candidates waiting for an organ in the US alone
• Versatile technique suitable for a variety of clinical indications
• High entry barrier for competition
• Comprehensive patent and IP protections in place
• Strong executive team with surgical research team having extensive
academic background and clinical experience in transplantation

5. 5
Organ Transplantation Today
In the U.S. ~31,000 organ transplants occur
every year but there are ~123,000 people on
the candidate waiting list for a transplant
Why is that the case?
Organ availability
• 22 people die each day in America waiting for
transplants that can’t take place because of the
shortage of donated organs
High costs and problems of anti-rejection drugs
• Average costs of the immunosuppressive drugs is
approximately $17,000 per year (Medicare only
covers the first three years)
• These drugs also cause increased infection and
cancer rates - ultimately destroy the organs
• Can still be rejection even with
immunosuppression
Donation Breakdown by Year

6. 6
Initial Target Market
Kidney transplants will be NuLife’s
initial target market
• Most common transplant – about
18,000 in 2015
• Most patients spend years on dialysis
while waiting
• Many never receive the actual
transplant
• All current transplant patients require
anti-rejection drugs
*Facts and statistics cited by the U.S. Department of Health & Human Services Organ
Procurement and Transplantation Network (OPTN), the Scientific Registry of Transplant
Recipients (SRTR) Annual Report, and www.organdonor.gov.

7. 7
The NuLife Technique
)
• Developed through 15 years of committed
research
• The result has been multiple breakthroughs in
hematopoietic research and transplant
techniques
• The goal of the research was to address the
issues of organ compatibility and the need for
anti-rejection drugs in the donor
• Pilot Studies:
• 1st surgery – 3 years ago
• 4 surgeries in total (2-3 animals per
surgery)

8. 8
The NuLife Technique
Novel, Patented Technique
1. Particular hematopoietic cells are used in the process as well as novel
temperature and pressure factors (under vacuum) methods
2. As a result of the vacuum process, specific cells are released from platelets
without complete platelet degranulation
3. The negative pressure created by the vacuum pulls the growth factors out of
the platelets and into the plasma
4. Once processed, the cells are reintroduced into the recipient influencing
further growth of an already implanted and recellularized organ
Implant
into donor
Recellularizing
process
Cell culture
process
Decellularization
per routine
procedures
Remove
kidney from
donor
Follows decellularization
processes to isolate the
extracellular matrix (ECM) of a
tissue from its inhabiting cells,
leaving an ECM scaffold of the
original tissue
With specific cells
harvested from bone
marrow of the
intended recipient

9. 9
Full Process in Stages
1 2 3
4 5 6
1. Removing kidneys from one patient (swine
anatomy and physiology are very similar to
humans)
2. Proceeding with decellularization process
3. Creation of a kidney ‘scaffold’, upon which
a new kidney specific to the recipient can
be rebuilt
4. The kidney scaffold is populated/injected
by bone marrow (immature) cells from the
recipient, allowing the stem cells to
differentiate into mature kidney cells.
5. Growth of a kidney that is genetically
identical to the recipient
6. The processed blood is given to the
recipient to aid the recellularization
process before and after the organ is
implanted.
The process allows for creation of organs that required no additional immunosuppression,
ultimately prolonging kidney longevity, and expands the population of usable kidneys.

10. 10
Kidney Decellularization
Pig kidney that has been
decellurized
Kidneys from the same pig - one has been decellurized
and the other one has not

11. 11
OPO Procures Organ
Attempt to Match
Transplant
Impact on the Transplant System
Donor organs are matched via national computer registry called the National Organ Procurement and Transplantation
Network (OPTN) – Organ Procurement Organization (OPO) has offices in all 50 states and serve as gatekeepers
OPO Procures Organ
Patient Identified
Transplant
Costs
• Anti-rejection drugs ($17K/yr)
• Dialysis while waiting ($85K/yr)
Quality of Life
• Anti-rejection drugs severely diminish quality
Mortality Rates
• 22 people per day die waiting
Cost impact of NuLife Process
• No anti-rejection drugs
• Little to no dialysis
Quality of Life
• No anti-rejection drugs
Mortality Rates
• Time to transplant is minimal
1 to 15
Years
Within
Days
Traditional NuLife

12. 12
Pathway to Commercialization
Data derived from clinical trial will be submitted to FDA, IRBs and other
regulatory bodies to determine final pathway to commercialization
Technology Discovery Preclinical Clinical
The NuLife
Technique
• Developed over 15
years
• Applied to wound
healing
• Patent applications
filed
• Patents issued in
2015
Animal experiments
1 experiment per month
with 3 animals for
+/- 12 experiments.
In collaboration with:
ü Complete appropriate
documentation
ü Expand advisory board
ü Meet with FDA to
propose clinical
pathway in 2017
Completed
• Preliminary animal
studies conducted
• Next studies
planned for 1H17
All of the organ transplant studies and procedures are being undertaken by the company's wholly-owned subsidiary, NuLife BioMed, Inc.

13. 13
Intellectual Property & Patents
• Three Patents Granted
• Existing Transplant Patent – filing CIP (claims in progress); will
have a fully issued patent with a 17-year window that starts at
conclusion of CIP
• Filing with the FDA to become licensed for use of cytokines
and/or a 14-year window of exclusivity for process and/or
therapy

14. 14
Additional Applications
• Transplantation of other vital organs (i.e. Liver)
• Study cytokine influence in sepsis
– May be able to improve mortality in infected patients
• Potential to boost immune system of healthy patients
• Potential to improve chronic wound closure
• Preventative care
• Can apply to several other conditions

15. 15
Management Team & Board
John Hollister, CEO
Executive with over 25 years of leadership experience in large pharmaceuticals, biotech (established and start-up), and medical device
(software and diagnostics). Extensive experience in all aspects of commercialization in the healthcare industry. In particular, strong
background in oncology, hematology, vaccines, and diabetes. John was previously CEO of Nemus Bioscience and served as a strategic
consultant working with early stage healthcare companies. He served as SVP of Marketing for Tethys Bioscience, a diabetes diagnostic
company and CEO of EEG Spectrum International, a private device company. He served in a series of Commercial positions, including the
Global Commercial Leader in Oncology at Amgen where he led multiple teams in developing oncology assets from preclinical to phase IV.
Prior to Amgen, Mr. Hollister started his pharmaceutical career at SmithKline Beecham. Mr. Hollister has his BA in Economics from Stanford
University and his MBA from the Drucker Center at the Claremont Graduate University.
Fred Luke, President
Mr. Luke serves as the President of NuLife. Fred has over 40 years of experience in providing operational and financial consulting services. He
has assisted companies with entity formation and business planning, multi-national mergers and acquisitions, reverse mergers, corporate
finance, debt restructuring, and arranging conventional debt and equity financing. Since 1970, Fred has provided consulting and
management services and has served as a director, chairman, chief accounting officer, president and chief executive officer of over 100
public and privately-held companies. He has worked in Asia, Europe, Canada, and North Africa. Fred’s clients have been active in various
business segments, domestic banking, the creation of domestic and foreign tax shelters, telecommunications, commercial airlines, real
estate, domestic film financing, clothing and food manufacturing, casino gaming and hotel operations, oil and gas exploration, oil and gas
transportation and refining, alternative energy, equipment leasing, network marketing, and international finance.
James Gandy, Founder
A wound care specialist, medical researcher, entrepreneur and patent developer. Mr. Gandy developed the process and corresponding
patents, which serve as the basis for the NuLife Technique. He serves as a consultant to the Company. James has spent years advancing a
number of medical breakthroughs- from wound care treatment to autoimmune disease. The more he learned about the human body, the
more eager he was to continue with his research. He made the bold decision to leave American Medical University in 2006 to dedicate all of
his time and attention to research in the area of cytokines and growth factors, and their use in the human body for tissue damage repair. He
has applied this knowledge and focused it on two main areas. One of those is the effects of cytokines and the other is in organ transplant.

16. 16
Medical Advisors
Dr. Juan Arenas, MD, FACS, MBA – Chief Medical Officer
As a board-certified transplant surgeon, Dr. Arenas is currently the Director of the Solid Organ Transplant Institute at Memorial Regional
Hospital in Hollywood, Florida. Prior to this role, he served as the Chief of the Division of Surgical Transplantation at UT Southwestern
Medical Center for 10 years. Dr. Arenas received his medical degree from Escuela Colombiana de Medicina in Bogota, Colombia, in 1987.
He completed a residency in general surgery at Pennsylvania State University School of Medicine in 1996, and a fellowship in
transplantation surgery at University of Pennsylvania Medical Center in 1997. Dr. Arenas has led research that rethinks organ preservation
and perfusion and has studied ways to reduce organ injury in donors after cardiac death. Dr. Arenas is certified by the American Society
of Transplant Surgeons as a multi-organ transplant surgeon. He is a Fellow of the American College of Surgeons, and also serves on the
Board of Directors.
Dr. Tjasa Hranjec, MD, MS-CR
Dr. Hranjec is a board certified general surgeon, specializing in Trauma, Critical care and Surgical Transplantation at Memorial Regional
Medical Center in Hollywood, Florida. She completed her general surgery residency at University of Virginia in Charlottesville, Virginia
and specialized in trauma, critical care and transplant at UT Southwestern Medical Center. She is well published in the areas of surgical
infection and has a strong interest in studying organ preservation and the effects of extracorporeal bypass in trauma and transplant
patients.
Dr. Youxue Wang, M.D., Ph.D.
Dr. Wang is a Senior Research Associate of Physiology & Pediatrics, currently working at the University of Texas Southwestern Medical
Center, Dallas, conducting research on cholestatic liver diseases. He has developed biosensors for coenzyme A (CoA), acetyl CoA and acyl
CoA in bile cell lines. In 1985, he graduated from Lanzhou Medical Collene in China as a Medical Doctor and specialized in
gastroenterology at the Lanzhou General Hospital. His research interests include transplantation, organ preservation, creation of animal
models.

17. 17
Contact Information
Investor Relations
Ted Haberfield
President – MZ North America
Direct: 760-755-2716
thaberfield@mzgroup.us
www.mzgroup.us